Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B.
Beatriz Mateos-MuñozMaría ButiInmaculada Fernández VázquezMarta Hernández CondeVanesa Bernal-MonterdeFernando Díaz-FontenlaRosa María MorillasLuisa García-BueyEster BadíaMireia MiquelAlberto Amador-NavarreteSergio Rodríguez-TajesLucía Ramos-MerinoAntonio MadejónMontserrat García-RetortilloJuan Ignacio ArenasJoaquín CabezasJesús Manuel González SantiagoConrado Fernández-RodríguezPatricia CorderoMoisés DiagoAntonio ManceboAlberto PardoManuel RodríguezElena HoyasJose Javier MorenoJuan TurnesMiguel Ángel SimónCristina Marcos-FoschJose Luis CallejaRafael BañaresSabela LensJavier Garcia-SamaniegoJavier CrespoManuel Romero-GomezFrancisco GeaEnrique Rodríguez de SantiagoSantiago MorenoAgustín Albillos MartínezPublished in: Digestive diseases and sciences (2023)
Compared to ETV, TDF seems to play a protective role in CHB patients with SARS-CoV-2 whereby the risk of severe COVID-19 is lowered.